Journal Article

CS-023 (R-115685), a novel carbapenem with enhanced <i>in vitro</i> activity against oxacillin-resistant staphylococci and <i>Pseudomonas aeruginosa</i>

Kenneth S. Thomson and Ellen Smith Moland

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 54, issue 2, pages 557-562
Published in print August 2004 | ISSN: 0305-7453
Published online August 2004 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dkh328
CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

Show Summary Details

Preview

Objective: To compare the in vitro activities of the carbapenem, CS-023, four representative β-lactam antibiotics and levofloxacin, against 970 Gram-positive or Gram-negative US clinical isolates.

Methods: Susceptibilities of bacteria chosen for their varying levels of resistance to the comparator agents were determined by NCCLS microdilution methodology.

Results: CS-023 exhibited activity comparable to that of imipenem against most Gram-positive isolates, but was ∼8-fold more potent against oxacillin-resistant staphylococci. It was comparable to meropenem against most Gram-negative isolates, but was 4- to 8-fold more potent against five isolates of meropenem-resistant Pseudomonas aeruginosa.

Conclusions: If tissue and body fluid concentrations >8 mg/L can safely be achieved, further studies of CS-023 are warranted to determine its clinical efficacy.

Keywords: carbapenems; β-lactams; imipenem; meropenem

Journal Article.  1879 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.